Trial Profile
A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Dronedarone (Primary)
- Indications Atrial fibrillation; Cardiovascular disorders
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms PALLAS
- Sponsors Sanofi
- 06 Apr 2022 This trial has been completed in Netherland (End Date: 21 Sep 2011), according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in Spain (End Date: 21 Sep 2011), according to European Clinical Trials Database record.
- 20 Sep 2011 New source identified and integrated (Clinical Trials Registry- India).